- Home
- LIMNW vs PHVS Comparison
LIMNW vs PHVS Comparison
Compare LIMNW & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIMNW
- PHVS
- Stock Information
- Founded
- LIMNW N/A
- PHVS 2015
- Country
- LIMNW United States
- PHVS Switzerland
- Employees
- LIMNW N/A
- PHVS N/A
- Industry
- LIMNW
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- LIMNW
- PHVS Health Care
- Exchange
- LIMNW Nasdaq
- PHVS Nasdaq
- Market Cap
- LIMNW N/A
- PHVS 909.5M
- IPO Year
- LIMNW N/A
- PHVS 2021
- Fundamental
- Price
- LIMNW $0.09
- PHVS $16.60
- Analyst Decision
- LIMNW
- PHVS Strong Buy
- Analyst Count
- LIMNW 0
- PHVS 5
- Target Price
- LIMNW N/A
- PHVS $39.20
- AVG Volume (30 Days)
- LIMNW N/A
- PHVS 59.4K
- Earning Date
- LIMNW N/A
- PHVS 05-13-2025
- Dividend Yield
- LIMNW N/A
- PHVS N/A
- EPS Growth
- LIMNW N/A
- PHVS N/A
- EPS
- LIMNW N/A
- PHVS N/A
- Revenue
- LIMNW N/A
- PHVS N/A
- Revenue This Year
- LIMNW N/A
- PHVS N/A
- Revenue Next Year
- LIMNW N/A
- PHVS N/A
- P/E Ratio
- LIMNW N/A
- PHVS N/A
- Revenue Growth
- LIMNW N/A
- PHVS N/A
- 52 Week Low
- LIMNW N/A
- PHVS $11.51
- 52 Week High
- LIMNW N/A
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- LIMNW N/A
- PHVS 52.79
- Support Level
- LIMNW N/A
- PHVS $15.46
- Resistance Level
- LIMNW N/A
- PHVS $16.50
- Average True Range (ATR)
- LIMNW 0.00
- PHVS 1.04
- MACD
- LIMNW 0.00
- PHVS -0.10
- Stochastic Oscillator
- LIMNW 0.00
- PHVS 75.33
About LIMNW Liminatus Pharma Inc. Warrants
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.